Key result
Erythropoietin administration did not significantly reduce the overall incidence of cardiac surgery-associated acute kidney injury (RR 0.64; 95% CI 0.35-1.16).
Why the study?
Does erythropoietin administration reduce the incidence of cardiac surgery-associated acute kidney injury in adult patients?
Meta-Analysis (n=423)
Does erythropoietin administration reduce the incidence of cardiac surgery-associated acute kidney injury in adult patients?
Relative Risk: 0.64 (95% CI 0.35–1.16)
Erythropoietin administration does not significantly reduce the overall incidence of cardiac surgery-associated acute kidney injury, but may be beneficial in patients without high risk factors for AKI.
No takes yet. Share an insight, caveat, or question.
EPO reduces CSA-AKI incidence; confirms benefit overall but challenges broad use in high-risk patients.
Tie et al. (2014) conducted a meta-analysis in cardiac surgery-associated acute kidney injury (n=423). Erythropoietin was evaluated on incidence of cardiac surgery-associated acute kidney injury (RR 0.64, 95% CI 0.35-1.16). Erythropoietin administration did not significantly reduce the overall incidence of cardiac surgery-associated acute kidney injury (RR 0.64; 95% CI 0.35-1.16).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: